Filomena Maiese departs ASMI
After nearly seven years with the Australian Self Medication Industry (ASMI), Director of Marketing & Business Development Filomena Maiese is departing to take up an exciting new challenge.
Ms Maiese will move to iNova Pharmaceuticals, where she will be Executive Director of Portfolio Strategy and Innovation across all regions. Her last day with ASMI will be 1 February.
"I feel privileged to have worked with an amazing group of experts at ASMI, all of whom are committed to advancing the non-prescription medicines industry," Ms Maiese said. "They are the unsung heroes behind a lot of positive industry reforms that are currently underway.
"I am sad to leave ASMI, but I am equally excited about my new role."
Ms Maiese has been instrumental in the successful advancement of key strategic industry initiatives, such as prescription to over-the-counter 'switch' and S3 consumer advertising. Under Ms Maiese's guidance, ASMI has developed key industry partnerships and driven crucial research initiatives that have been vital to advancing the non-prescriptions medicines sector and providing essential evidence to support key industry asks to regulatory bodies and stakeholders. Prior to joining ASMI, Ms Maiese headed up Johnson & Johnson Pacific's ANZ OTC business unit.
Ms Maiese will now focus on driving expansion plans for iNova, developing new product and innovation pipelines across all markets.
Brenda Davy will move from a part-time to full-time role at ASMI, taking on the position of Director of Business Development immediately upon Ms Maiese's departure. Ms Davy will continue to lead strategic projects and provide support to the Stakeholder Management Subcommittee in addition to taking up many of Ms Maiese's ongoing responsibilities, including management of member and industry engagement, ASMI events and services, and the Marketing & Ethics Subcommittee.
"In her almost seven years with ASMI, Filomena made enormous contributions to the association, and I would like thank her on behalf the membership and the ASMI team," ASMI CEO Deon Schoombie said.
"It was a pleasure working with Filomena, she was a source of energy and enthusiasm. We wish her all the best in the new role."